120
Participants
Start Date
May 22, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
VNX001
VNX001 (alkalinized lidocaine HCl and heparin sodium)
Placebo
Inactive placebo for VNX001
Lidocaine
Alkalinized lidocaine hydrochloride
Heparin
Alkalinized heparin sodium
RECRUITING
Northwell Health, Lake Success
RECRUITING
The Wake Forest Institute of Regenerative Medicine, Winston-Salem
SUSPENDED
Georgia Urology, Cartersville
RECRUITING
United Research Institute, Hialeah
RECRUITING
Florida Urology Partners, Tampa
RECRUITING
Southern Clinical Research Associates LLC, Metairie
RECRUITING
Sheldon Freedman MD LTD, Las Vegas
COMPLETED
University of California Los Angeles Center for Women's Pelvic Health, Los Angeles
SUSPENDED
IC Study LLC, Escondido
RECRUITING
University of California San Diego Medical Center, San Diego
RECRUITING
The Clark Center for Urogynecology, Newport Beach
COMPLETED
The Continence Center Medical Group, Inc dba Southern California Continence Center, Newport Beach
RECRUITING
Prestige Medical Group, Tustin
RECRUITING
Bay State Clinical Trials, Watertown
Prevail Infoworks
INDUSTRY
Vaneltix Pharma, Inc.
INDUSTRY